Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BRE12-158
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
- NCT02101385 ↗
- Completed
- Bryan Schneider, MD
- Focused
We haven't built an HCP commentary report on BRE12-158 (genomically directed in Malignant Neoplasm of Breast) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BRE12-158 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Malignant Neoplasm of Breast; Breast Cancer
- Interventions
- Genomically Directed Monotherapy; Observation/Standard Therapy
- Arms
- Arm A (Genomically Directed Monotherapy) · Experimental
- Control Arm B (Observation/Standard Therapy) · Other
- Enrollment
- 193
- Primary outcomes
- Percentage of Participants With Two-Year Disease-Free Survival (DFS)
- Sponsor
- Bryan Schneider, MD with Hoosier Cancer Research Network, Vera Bradley Foundation for Breast Cancer, Walther Cancer Institute, Indiana University
- Start
- Apr 3, 2014
- Primary completion
- Feb 21, 2021
- Results posted
- Yes
- Registry record
- NCT02101385 · updated Sep 28, 2023
Publications
linked from the registry- Xu J, Gao H, Guan X, Meng J, Ding S, Long Q, Yi W. Circulating tumor DNA: from discovery to clinical application in breast cancer. Front Immunol. 2024 Apr 30;15:1355887. doi: 10.3389/fimmu.2024.1355887. eCollection 2024. PubMed 38745646
- Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Hancock BA, Kassem N, Helft P, O'Neil B, Storniolo AMV, Badve S, Miller KD, Radovich M. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 Feb 1;40(4):345-355. doi: 10.1200/JCO.21.01657. Epub 2021 Dec 15. PubMed 34910554
- Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295. PubMed 32644110